"Cough"

Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in Australia closeperson_outline LOGINPUBLISH WITH USCURRENT ISSUEONLINE FIRSTARCHIVEINSIGHT+TOPICSkeyboard_arrow_downARTICLE TYPESkeyboard_arrow_downPODCASTSJOBS BOARDCONNECTEDBOOKSHOPCONNECT THE MEDICAL JOURNAL OF AUSTRALIAperson_outline LOGINkeyboard_arrow_downmenu PUBLISH WITH US COVID-19 ONLINE FIRST ARCHIVE keyboard_arrow_down PODCASTSsearchAdvertisementclosePOSITION STATEMENT SUMMARYOPEN ACCESS  CC-BY-NC-ND   ONLINE FIRSTCough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in AustraliaJulie M Marchant, Anne B Chang, Emma Kennedy, David King, Jennifer L Perret, Andre

A multifaceted intervention to reduce antibiotic prescribing among CHIldren with acute COugh and respiratory tract infection: the CHICO cluster RCT Text onlyJournals LibraryNHS NIHR - National Institute for Health ResearchSelectEMEGHRHSDRHTAPGfARPHR AdvancedJournalsEfficacy and Mechanism EvaluationGlobal Health ResearchHealth and Social Care Delivery ResearchHealth Technology prescribing among CHIldren with acute COugh and respiratory tract infection: the CHICO cluster RCTPeter S Blair, Grace J Young, Clare Clement, Padraig Dixon, Penny Seume, Jenny Ingram, Jodi Taylor, Jeremy Horwood, Patricia J Lucas, Christie Cabral, Nick A Francis, Elizabeth Beech, Martin Gulliford, Sam Creavin, Janet A Lane, Scott Bevan & Alastair D Hay.Detailed Author informationFunding: Health Technology

Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) Technology appraisal guidance Published: 30 April 2024 www.nice.org.uk/guidance/ta969 © NICE 2024. All rights reserved. Subject to Notice of rights ( Advice ................................................................................................................................3 Information ..................................................................................................................................3 Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)(TA969)© NICE 2024. All rights reserved. Subject to Notice of rights ( 2of 3 Advice NICE is unable to make a recommendation about the use in the NHS of gefapixant

Assessment of chronic cough Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageAssessment of chronic cough MENUThis topic is available for freeLast reviewed:7 May 2023Last updated:02 Jun 2023SummaryCough is one of the most common presenting symptom in primary practice.[1] Sub-acute cough is defined as cough persisting for 3-8 weeks, and chronic cough as that persisting for more than 8 weeks in adults.[2][3] Chronic cough in children has been defined as the presence of cough every day for 4 weeks or more.[4] Sub-acute cough is most often self-limiting, but chronic cough may provide significant challenges for effective evaluation and management. The difficulty is in determining the cause of cough, because some

Upper airway cough syndrome Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchUpper airway cough syndrome MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:9 Jul 2023Last updated:08 Aug 2023SummaryChronic cough that occurs with coexisting upper airway symptoms, including abnormal sensations arising from the throat and a postnasal drip sensation.Sensations attributed to nasal disease may actually be manifestations of a sensory neuropathic process and not relate to rate or quantity of nasal discharge.Most common cause of chronic cough in adults.No pathognomonic findings exist; diagnosis should be determined by considering a combination of criteria, including the history, physical exam, imaging

Coughing up the evidence: Bronchodilators or inhaled steroids for post-infectious cough TOOLS FOR PRACTICE #329 | December 12, 2022 Coughing up the evidence: Bronchodilators or inhaled steroids for post-infectious cough CLINICAL QUESTION Do bronchodilators or inhaled corticosteroids (ICS) improve post-infectious cough in adults without asthma? BOTTOM LINE Data is very limited with only two ICS randomized controlled trials (RCTs) (163 patients) and one bronchodilator RCT (92 patients). For adults, post-infectious cough scores may improve ~50% on placebo and ~5-10% more with ICS over 2 weeks. Ipratropium/salbutamol may resolve cough in more patients than placebo at day 10 (69% versus 37%) but most patients (>80%, regardless of treatment) will have cough resolution by day 20

Gefapixant (Lyfnua) - chronic (long-term) cough Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The NetherlandsAddress for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000An agency of the European Union © European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged.EMA/342744/2023 EMEA/H/C/005476Lyfnua (gefapixant)An overview of Lyfnua and why it is authorised in the EUWhat is Lyfnua and what is it used for?Lyfnua is a medicine used to treat adults with chronic (long-term) cough which is unexplained or for which other treatments have not worked. The medicine contains the active substance gefapixant.How is Lyfnua used?Lyfnua is available

Whooping cough CKS is only available in the UK | NICE CKS is only available in the UKThe NICE Clinical Knowledge Summaries (CKS) site is only available to users in the UK, Crown Dependencies and British Overseas Territories.CKS content is produced by Clarity Informatics Limited. It is available to users outside the UK via subscription from the Prodigy website.If you believe you are seeing

Whooping cough: vaccination in pregnancy programme resources Whooping cough: vaccination in pregnancy programme resources - GOV.UK Cookies on GOV.UKWe use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content GOV.UK Search 1. Home 2. Parenting, childcare and children's services 3. Children's health and welfare 4. Children's health Promotional material Whooping cough: vaccination in pregnancy programme resources Information leaflet and poster to support the whooping cough vaccination in pregnancy programme. From: UK Health Security Agency Published 28 September 2012 Last updated 26 June 2024 — See all

Vaccination against pertussis (whooping cough) for pregnant women Vaccination against pertussis (whooping cough) for pregnant women - GOV.UK Skip to main content Cookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites account: sign in 1. Home 2. Health and social care 3. Public health 4. Health protection 5. Immunisation Guidance Vaccination against pertussis (whooping cough) for pregnant women This vaccination programme helps protect infants from whooping cough by boosting pertussis immunity in pregnant women. From: UK Health Security Agency Published 24 June 2014 Last updated 6 September 2021 — See all

Camlipixant for treating refractory or unexplained chronic cough Camlipixant for treating refractory or unexplained chronic cough - NIHR Innovation Observatory * Who we are * What we do * Our Networks * Engage * Events * News * Resources Get in touch * * A world leading Horizon Scanning Facility The NIHR Innovation Observatory is a world leading health and care innovation scanning centre of adults with refractory or unexplained chronic cough. Cough is a normal reflex response to airway irritation, triggered by stimulation of airway cough receptors, which protect against choking and enhance airway clearance. Camlipixant is in clinical development for the treatment of adults with refractory or unexplained chronic cough. Cough is a normal reflex response to airway irritation, triggered

Cough and Cold Products Containing Opioids: Prescribing and Patient Utilization Patterns in the Pediatric Population Skip to main contentSkip to "About this site"Switch to basic HTML versionSearch and menusSearch and menusCanadian Institutesof Health ResearchYou are here:Home Initiatives Drug Safety and Effectiveness NetworkDSEN AbstractCough and Cold Products Containing Opioids: Prescribing and Patient Utilization Patterns in the Pediatric PopulationOther formatPDF version(143 KB)What is the current situation?High levels of prescription opioid use in Canada are cause for concern. Many cough and cold prescription products (CCOMs) contain codeine, hydrocodone or normethadone. Although these products, like opioids, may be misused and abused, no current data are available to quantify

Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure Skip to main contentCookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites to help us deliver content from their services.Accept additional cookiesReject additional cookiesView cookies GOV.UKNavigation menuMenuSearch GOV.UKHomeDrug Safety UpdatePholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measureAdvice for healthcare professionals regarding the withdrawal of pholcodine-containing medicines from the market.From:Medicines and Healthcare products Regulatory AgencyPublished14

Palliative care - cough CKS is only available in the UK | NICE CKS is only available in the UKThe NICE Clinical Knowledge Summaries (CKS) site is only available to users in the UK, Crown Dependencies and British Overseas Territories.CKS content is produced by Clarity Informatics Limited. It is available to users outside the UK via subscription from the Prodigy website.If you believe you

Cough - acute with chest signs in children CKS is only available in the UK | NICE CKS is only available in the UKThe NICE Clinical Knowledge Summaries (CKS) site is only available to users in the UK, Crown Dependencies and British Overseas Territories.CKS content is produced by Clarity Informatics Limited. It is available to users outside the UK via subscription from the Prodigy website.If you

Cough (acute): antimicrobial prescribing Cough (acute): antimicrobial prescribing NICE guideline Published: 7 February 2019 www.nice.org.uk/guidance/ng120 © NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cough (acute): antimicrobial prescribing (NG120)© NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 2 of42Contents Contents Overview

The efficacy and safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) on cough symptoms in adult patients with asthma, A randomized double-blind, placebo-controlled, parallel group study: Chronic Cough in Asthma (COCOA) study. Persistent cough bothers many patients with asthma because it worsens their quality of life; therefore, it must be remedied immediately. The efficacy of triple therapy as a first-line treatment for cough remains unclear. To evaluate the effectiveness and safety of the triple therapy againts persistent cough, the clinical effect of regular treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or placebo in adult patients with asthma was investigated. This randomized, double-blind, placebo-controlled, parallel-group multicentre trial

The McMaster Cough Severity Questionnaire (MCSQ): a cough severity instrument for patients with refractory chronic cough. Cough severity represents an important endpoint to assess the impact of therapies for patients with refractory chronic cough (RCC). To develop a new patient-reported outcome measure addressing cough severity in patients with RCC. Phase 1 (item generation): A systematic survey (Cronbach's alpha, 0.89), proved able to distinguish different levels of cough severity (Pearson separation index, 0.89), and demonstrated high cross-sectional convergent validity (Pearson's correlation, 0.76 [95% CI 0.66 to 0.83]) with the 100-mm cough severity visual analogue scale. Initial evidence supports the validity of the MCSQ, an 8-item instrument measuring cough severity in patients with RCC

The Japanese respiratory society guidelines for the management of cough and sputum (digest edition) Cough and sputum are common complaints at outpatient visits. In this digest version, we provide a general overview of these two symptoms and discuss the management of acute (up to three weeks) and prolonged/chronic cough (longer than three weeks). Flowcharts are provided, along with a step-by-step explanation of their diagnosis and management. Most cases of acute cough are due to an infection. In chronic respiratory illness, a cough could be a symptom of a respiratory infection such as pulmonary tuberculosis, malignancy such as a pulmonary tumor, asthma, chronic obstructive pulmonary disease, chronic bronchitis, bronchiectasis, drug-induced lung injury, heart failure, nasal sinus disease

Cough CKS is only available in the UK | NICE CKS is only available in the UKThe NICE Clinical Knowledge Summaries (CKS) site is only available to users in the UK, Crown Dependencies and British Overseas Territories.CKS content is produced by Clarity Informatics Limited. It is available to users outside the UK via subscription from the Prodigy website.If you believe you are seeing this page